CN1248697C - Medicinal composition for treating chronic enteritis and its preparing process - Google Patents
Medicinal composition for treating chronic enteritis and its preparing process Download PDFInfo
- Publication number
- CN1248697C CN1248697C CN 200310113283 CN200310113283A CN1248697C CN 1248697 C CN1248697 C CN 1248697C CN 200310113283 CN200310113283 CN 200310113283 CN 200310113283 A CN200310113283 A CN 200310113283A CN 1248697 C CN1248697 C CN 1248697C
- Authority
- CN
- China
- Prior art keywords
- olibanum
- chronic enteritis
- metronidazole
- rifampicin
- myrrha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000021735 chronic enteritis Diseases 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims description 3
- 239000003814 drug Substances 0.000 claims abstract description 43
- 241000717739 Boswellia sacra Species 0.000 claims abstract description 24
- 239000004863 Frankincense Substances 0.000 claims abstract description 24
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229960000282 metronidazole Drugs 0.000 claims abstract description 22
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229960001732 pipemidic acid Drugs 0.000 claims abstract description 22
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims abstract description 21
- 229960001225 rifampicin Drugs 0.000 claims abstract description 21
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 239000002775 capsule Substances 0.000 claims abstract description 8
- 241001057584 Myrrha Species 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 13
- 239000002994 raw material Substances 0.000 abstract description 4
- 240000007311 Commiphora myrrha Species 0.000 abstract description 2
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract description 2
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 235000008216 herbs Nutrition 0.000 abstract 1
- 229940126673 western medicines Drugs 0.000 abstract 1
- 230000003203 everyday effect Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 230000013872 defecation Effects 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000007413 intestinal health Effects 0.000 description 3
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 229910000014 Bismuth subcarbonate Inorganic materials 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 2
- 229960002028 atropine sulfate Drugs 0.000 description 2
- MGLUJXPJRXTKJM-UHFFFAOYSA-L bismuth subcarbonate Chemical compound O=[Bi]OC(=O)O[Bi]=O MGLUJXPJRXTKJM-UHFFFAOYSA-L 0.000 description 2
- 229940036358 bismuth subcarbonate Drugs 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 2
- 229960004192 diphenoxylate Drugs 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- RJWLLQWLBMJCFD-UHFFFAOYSA-N 4-methylpiperazin-1-amine Chemical compound CN1CCN(N)CC1 RJWLLQWLBMJCFD-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010059447 Allergic colitis Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241001608538 Boswellia Species 0.000 description 1
- 235000018062 Boswellia Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 201000007637 bowel dysfunction Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000009740 moulding (composite fabrication) Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a drug composition for treating chronic enteritis and a preparation method thereof. The drug composition is prepared from traditional Chinese medicinal herbs and Western medicines as raw materials. The drug composition comprises the following components of the proportion by weight: 4 to 8 parts of olibanum, 4 to 8 parts of myrrh, 1 to 5 parts of rifampicin, 4 to 8 parts of pipemidic acid and 7 to 11 parts of metronidazole; the drugs are crushed, mixed, sieved and prepared into various kinds of preparations, particularly a capsule according to the conventional preparation method. The total effective rate of the drug composition for treating chronic enteritis in clinic is 97.6% observationally, and compared with the control group, the drug composition has the advantages of conspicuous curative effect and no toxic or side effect.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of chronic enteritis and preparation method thereof, relate in particular to a kind of pharmaceutical composition of the treatment chronic enteritis made from traditional Chinese herbal medicine and Western medicine raw material.
Background technology
Chronic enteritis belongs to that the traditional Chinese medical science " is had loose bowels ", " sharp disease ", " hemorrhoidal hamorrhage " category, belongs to chronic gastroenteritis, chronic colitis, the allergic colitis of modern medicine, belongs to that reason such as bowel dysfunction causes, and primary disease talks easily, controls very thorny.Chronic enteritis is old, young, few commonly encountered diseases, frequently-occurring disease.Common have Diphenoxylate Mixture of hydrochloride with atropine sulfate, a gentamycin sulfate and bismuth subcarbonate capsules etc., Drug therapy, and curative effect is slow, weak effect, and recurrence easily, or have toxic and side effects,
Summary of the invention
The purpose of this invention is to provide a kind of pharmaceutical composition for the treatment of chronic enteritis and preparation method thereof, a kind of pharmaceutical composition of the treatment chronic enteritis made from Chinese herbal medicine and Western medicine raw material especially is provided, overcome the shortcoming of said medicine.
The objective of the invention is to be achieved through the following technical solutions:
A kind of pharmaceutical composition for the treatment of chronic enteritis is by the medicament that comprises that following component is made: Olibanum, Myrrha, rifampicin, pipemidic acid, metronidazole;
Myrrha is the dry gum resin of myrrh, bitter in the mouth, and property is flat.Go into the heart, Liver Channel.Can invigorate blood circulation and get the stasis of blood, eliminating carbuncle pain relieving.
Olibanum is the dry gum resin of Boswellia carterii, bitter in the mouth, and suffering, warm in nature.Go into the heart, Liver Channel.Energy blood circulation promoting and blood stasis dispelling, eliminating carbuncle pain relieving.
Rifampicin is lifumeisu (antibiotic that Streptothrix produces), and lifumeisu reduces through vitamin C in sulphuric acid, and gets with 1-methyl-4-aminopiperazine condensation.
Pipemidic acid is a carbostyril family antibacterial drugs, has stronger effect to killing or suppressing microorganism.
Metronidazole has another name called nitre hydroxyl second azoles, is antiprotozoal drug.
Raw material of the present invention all can be purchased in market.
Described component can be following parts by weight of component: Olibanum 4-8, Myrrha 4-8, rifampicin 1-5, pipemidic acid 4-8, metronidazole 7-11;
Described component is preferably following parts by weight of component: Olibanum 5-7, Myrrha 5-7, rifampicin 2-4, pipemidic acid 5-7, metronidazole 8-10;
Described component is preferably following parts by weight of component: Olibanum 6, Myrrha 6, rifampicin 3, pipemidic acid 6, metronidazole 9.
Described medicament can be any pharmaceutically said dosage form, especially is capsule, pill, tablet, granule.
The present invention also provides the preparation of drug combination method of described treatment chronic enteritis, may further comprise the steps: take by weighing Olibanum, Myrrha, rifampicin, pipemidic acid, metronidazole according to the above ratio, pulverize, mix, sieve, the preparation method is made various preparations routinely again.
Medicine of the present invention is based on that following mechanism is prepared from: medicine of the present invention is the compound preparation of making in conjunction with modern medicine on the basis of Traditional Chinese medical theory.Its mechanism is:
The Main Ingredients and Appearance of this medicine is Olibanum, Myrrha, supplement to the Herbal has the effect of " end large intestine and let out Bleach ", Chinese materia medica discuss have invigorate blood circulation, relieve the pain, the function of granulation promoting, skin ulcer is closed up, and clinical observation is effective equally to the gastrointestinal ulceration inflammation, and modern medicine study thinks that Olibanum, Myrrha have extremely strong covering power to gastrointestinal mucosa, can become the barrier of mucosa, and fixing enterovirus, antibacterial and toxin thereof impel the mucosa infection reparation.
Rifampicin, metronidazole, pipemidic acid can suppress to kill sharp Shigella, cholera bacteria, salmonella, Non-cholera vibrio, crooked bacterium and enterobacteria strongly in this medicine, assist Olibanum, Myrrha to kill and remove mucosa antibacterial, toxin, impel the human body rehabilitation.
This medicine is an Integrative Chinese-Western, acts synergistically on gastrointestinal gland parietal cell, has suppressed gastrointestinal secretion, has strengthened hemostasis, pain relieving, antimicrobial function; Stimulated the gastrointestinal hypodermal cell, the healing of ulcer surface has been quickened in the hypertrophy of epithelial cell tissue, division.After this medicine Integrative Chinese-Western, the immunity of collaborative adjusting human body has suppressed inflammation and immunoreation, has alleviated signs of toxicity, has improved intestinal environment, has promoted the absorption of inflammation, particularly share back antimicrbial power multiplication, and immunity strengthens, and has obtained curative effect preferably.
On probation by clinical observation: this medicine is efficient, safety, and addiction is not difficult for recurrence after healing, and is fit to out-patient treatment, worth clinical expansion.Pharmacological action shows that this medicine all has good antibacterial efficacy to sharp Shigella and other pathogenic entero becteria, mainly is applicable to treatment acute chronic enteritis, bacillary dysentery, colitis, Anaphylaxis enteritis, refrigerator enteritis etc.
For proving therapeutic effect of the present invention, carried out following clinical trial: select the embodiment of the invention 1 medicine (slow intestinal health) treatment chronic enteritis 210 examples for use, clinical observation, the satisfaction of producing effects.
1, clinical data: 210 patients are the out-patient between year July in January, 1999 to 2003, meet national chronic diarrhea academic discussion case choice criteria in 1986.Wherein, the treatment group: male 120 examples, women 90 examples, in age 9-75 year, the course of disease is the shortest 2 months, and is the longest 30 years; Matched group: male 80 examples, women 30 examples, in age 12-67 year, the course of disease is the shortest 1 month, and is the longest 20 years; Two groups have comparability.
2, Therapeutic Method
The treatment group: give embodiment 1 capsule (slow intestinal health), Main Ingredients and Appearance Olibanum, Myrrha, Li Fuping, pipemidic acid, metronidazole, every 0.5g, each 6, every day three times, one after each meal, this medicine is to quinolone medicine allergy sufferers forbidding, and infant is forbidden; Routed intestinal of hepatic and kidney function obstacle person, hypertension, diabetes, stomach and duodenum and the careful usefulness of heart failure; After taking medicine, urinating rubescent is the medicine normal reaction.Matched group: 2 of Diphenoxylate Mixture of hydrochloride with atropine sulfate, every day three times; 4 of gentamycin sulfate and bismuth subcarbonate capsules, every day 1 time.Two groups was a course of treatment with 10 days all, serve on 2 courses of treatment, estimated therapeutic effect.Observe times of defecation, character every day during the treatment.
3, therapeutic effect
3.1 efficacy assessment standard, referring to " diagnosis of common case and curative effect determinate standard " (the 1st edition, Wu Shaozhen etc., Beijing, China Traditional Chinese Medicine Publishing House, 1999,305-306)
Cure: transference cure, defecation is normal, above nothing recurrence in January; Produce effects: transference cure, the recurrence once more of suffering from cold; Effectively: the defecation of taking medicine is normal, the abnormal defecation of not taking medicine; Invalid: symptom after taking medicine does not all have improvement.
3.2 therapeutic effect (seeing Table 1)
Table 1 Drug therapy chronic enteritis of the present invention effect
| Group | The example number | Cure | Produce effects | Effectively | Invalid | Effective percentage % |
| The treatment group | 210 | 145 | 35 | 25 | 5 | 97.6％ |
| Matched group | 110 | 27 | 23 | 20 | 40 | 36.36 |
4, model case
Lee, man, 47 years old, on March 12nd, 1999 is with the chronic enteritis first visit, private prosecution stomachache, diarrhoea outbreak more than 20 year, sometimes in anxious state of mind, feed, when greasy, loose stool has mucus in just, gently every day 2-3 time then, heavy then every day 6-7 time, sometimes had a pain under the umbilicus before dawn, borborygmus are promptly let out, and eat a little Western medicine, Chinese patent medicine, heavy when time thes be light, touching difficulty more.The pallor of having a medical check-up cold extremities, physical fatigue and lassitude of spirit, indigestion and loss of appetite, abdominal part is latent has a pain, and examines its deep-thready pulse, and the tongue skin is light, and is white greasy, controls with the above-mentioned slow intestinal health of the present invention for oral administration, takes medicine 10 days, and symptom is clearly better, and takes medicine again 10 days, and all diseases disappear, and recovery from illness is followed up a case by regular visits to so far, recurrence again.
The specific embodiment
Embodiment 1
Capsule
Take by weighing following medicine material (Kg): Olibanum 6, Myrrha 6, rifampicin 3, pipemidic acid 6, metronidazole 9.
Preparation method: take by weighing Olibanum, Myrrha, rifampicin, pipemidic acid, metronidazole according to the above ratio, pulverize, mix, 100 orders that sieve, encapsulated, ultraviolet is sterilized promptly.
Specification: 0.5g * 100.Usage and consumption: oral; Every day three times, each 6, one after each meal, or follow the doctor's advice.
Embodiment 2
Capsule
Take by weighing following medicine material (Kg): Olibanum 5, Myrrha 5, rifampicin 2, pipemidic acid 5, metronidazole 8.
Preparation method: with embodiment 1.
Embodiment 3
Tablet
Take by weighing following medicine material (Kg): Olibanum 7, Myrrha 7, rifampicin 4, pipemidic acid 7, metronidazole 10.
Preparation method: take by weighing Olibanum, Myrrha, rifampicin, pipemidic acid, metronidazole according to the above ratio, pulverize, mix, 60% ethanol granulate is crossed 14 mesh sieves, adds magnesium stearate 200g, and tablet forming promptly behind the abundant mix homogeneously.
Embodiment 4
Pill
Take by weighing following medicine material (Kg): Olibanum 4, Myrrha 4, rifampicin 1, pipemidic acid 4, metronidazole 7.
Preparation method: take by weighing Olibanum, Myrrha, rifampicin, pipemidic acid, metronidazole according to the above ratio, pulverize, mix,, cross 200 mesh sieves with 60% ethanol granulate, tablet forming, sugar coating, sterilization, promptly.
Embodiment 5
Granule
Take by weighing following medicine material (Kg): Olibanum 8, Myrrha 8, rifampicin 5, pipemidic acid 8, metronidazole 11.
Preparation method: take by weighing Olibanum, Myrrha, rifampicin, pipemidic acid, metronidazole according to the above ratio, pulverize, mix, make granule, cross 10 mesh sieves with 55% ethanol, packing, sterilization, promptly.
Claims (5)
1, a kind of pharmaceutical composition for the treatment of chronic enteritis is made by following bulk drugs: Olibanum 4-8, Myrrha 4-8, rifampicin 1-5, pipemidic acid 4-8, metronidazole 7-11.
2, the pharmaceutical composition of treatment chronic enteritis according to claim 1 is characterized in that the weight portion of each crude drug is: Olibanum 5-7, Myrrha 5-7, rifampicin 2-4, pipemidic acid 5-7, metronidazole 8-10.
3, the pharmaceutical composition of treatment chronic enteritis according to claim 2 is characterized in that the weight portion of each crude drug is: Olibanum 6, Myrrha 6, rifampicin 3, pipemidic acid 6, metronidazole 9.
4, the pharmaceutical composition of treatment chronic enteritis according to claim 1 and 2, the preparation that it is characterized in that described pharmaceutical composition is capsule, pill, tablet or granule.
5, a kind of method for preparing the described arbitrary pharmaceutical composition of claim 1-4, may further comprise the steps: take by weighing Olibanum, Myrrha, rifampicin, pipemidic acid, metronidazole in the described arbitrary ratio of claim 1-3, pulverize, mix, sieve, the preparation method is made various preparations routinely again.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310113283 CN1248697C (en) | 2003-11-13 | 2003-11-13 | Medicinal composition for treating chronic enteritis and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310113283 CN1248697C (en) | 2003-11-13 | 2003-11-13 | Medicinal composition for treating chronic enteritis and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1544041A CN1544041A (en) | 2004-11-10 |
| CN1248697C true CN1248697C (en) | 2006-04-05 |
Family
ID=34336804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310113283 Expired - Lifetime CN1248697C (en) | 2003-11-13 | 2003-11-13 | Medicinal composition for treating chronic enteritis and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1248697C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0519426A2 (en) * | 2004-12-28 | 2009-01-20 | Meiji Seika Kaisha | lineage conferring antigenic properties to the bacterial and host cell composition |
| CN105250305B (en) * | 2015-10-13 | 2019-02-01 | 康普药业股份有限公司 | A kind of pipemidic acid pharmaceutical composition |
-
2003
- 2003-11-13 CN CN 200310113283 patent/CN1248697C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1544041A (en) | 2004-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1785359A (en) | Chinese medicinal preparation for treating gastroenteric disease | |
| CN1331502C (en) | Chinese medicine composition | |
| RU2419449C1 (en) | Medication for treatment of patients with drug hepatitis | |
| CN101095868A (en) | Medicine composition for treating colitis and method of making the same | |
| CN1248697C (en) | Medicinal composition for treating chronic enteritis and its preparing process | |
| CN1284585C (en) | Medicine for treating acute and chronic pharyogolaryngitis, recurring oral cavity sore and its preparation method | |
| CN102078549A (en) | Traditional Chinese medicine for treating oxyuriasis | |
| CN108939011A (en) | A kind of Chinese herbal medicine formula for the treatment of cancer | |
| CN1141966C (en) | Stone expelling medicine powder | |
| CN105031488A (en) | Traditional Chinese medicinal composition for treating enterogastritis | |
| CN100493525C (en) | Ointment for treating tonsillitis | |
| CN101204554B (en) | Medicaments composite for stomach illness and preparation method thereof | |
| CN1294919C (en) | Externally used medicine bag for treating piles and preparation method thereof | |
| CN1163116A (en) | Compound health medicinal emblic tablet and its producing technology | |
| CN104707008B (en) | A kind of composite drug and preparation method for preventing chickens respiratory disease | |
| CN1730091A (en) | Medicine for curing lithangiuria | |
| CN103585580A (en) | Chinese medicinal preparation for treating recurrent oral ulceration | |
| CN100509003C (en) | Medicament of treating psoriasis | |
| Kumar et al. | Impact of Ingudi (Balanites aegyptiaca Linn. Delile) Seed oil on Prameha Pidika (Diabetic Carbuncle): A Case Study | |
| CN1301741C (en) | Chinese medicinal capsule for treating blood stasis pattern protracted diarrhea due to intestine erosion and ulcer | |
| CN1500505A (en) | Medication composition for children 's virus pneumonia and its preparation method | |
| CN104784332B (en) | A kind of preparation method of the medicament treating Chronic Urinary Tract Infection | |
| CN117838823A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN113144065A (en) | Surgical Shenying pill and preparation method thereof | |
| CN101766604A (en) | Preparation method and pharmaceutical uses of curcumin and pidotimod composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: XUN HONGRUN Free format text: FORMER NAME: XUN HUANREN |
|
| CP03 | Change of name, title or address |
Address after: The village of Yang Li Tai Zhen Lao Jia Xing Zheng Cun Dancheng County in Henan province 477161 No. 0001 Wu Patentee after: Xun Hongrun Address before: Li Ge health Yang Lao Jia Xing Zheng Cun town Dancheng County in Henan province 477161 Wu Patentee before: Xun Huanren |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060405 |